Spots Global Cancer Trial Database for Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain
Official Title: Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain
Study ID: NCT03181984
Conditions
Interventions
Study Description
Brief Summary: This study is to provide safety information of hemoporfin during the post-marketing period as required by China Food and Drug Administration (CFDA) regulations in order to identify any potential drug related treatment factors in the Chinese population, such as unknown/unexpected adverse reactions, the incidence of adverse reactions under the routine drug uses.
Detailed Description:
Keywords
Eligibility
Minimum Age: 14 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The 2nd Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Affiliated Hospital of Hebei Medical College of traditional Chinese Medicine, Shijiazhuang, Herbei, China
Wuxi People's Hospital, Wuxi, Jiangsu, China
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Peking University First Hospital, Beijing, , China
PLA Army General Hospital, Beijing, , China
Shanghai Dermatology Hospital, Shanghai, , China
Contact Details
Name: Xuejun Zhu
Affiliation: Peking University First Hospital
Role: PRINCIPAL_INVESTIGATOR
Name: Jining Tao
Affiliation: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
